Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers.

Neoplastic growth and dissemination involve increased proteolytic activity that is able to escape the regulative elements. Matrix metalloproteinases (MMPs), particularly gelatinases A and B (MMP-2 and -9), play a role in tumor invasion and angiogenesis, and they participate in cancer progression in several neoplasias. The expression of tissue inhibitors of gelatinases, TIMPs-1 and -2, has also been shown to be associated with the clinical course in some cancers. The prognostic value of these markers, however, seems to vary a great deal in different neoplastic diseases. In this review, the impact of the gelatinases and their inhibitors on the clinical course in several solid cancers is evaluated based on the growing data from recent clinical studies. The clinical data most often explore the overexpression of mRNA or immunoreactive protein in tumor tissue, or measure the concentration of the circulating proteinase or its inhibitor in pretreatment or follow-up serum samples. The growing amount of recent clinical data suggests that the impact of gelatinases on treatment decisions should be tested in clinical trials.

[1]  T. Thompson,et al.  Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. , 1998, The American journal of pathology.

[2]  J. Guillem,et al.  Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Giannopoulou,et al.  Correlation of Tissue Inhibitor of Metalloproteinase-2 with Proliferative Activity and Patients’ Survival in Breast Cancer , 2002, Modern Pathology.

[4]  U. Puistola,et al.  Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. , 2004, Gynecologic oncology.

[5]  H. Verspaget,et al.  Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. , 1996, British Journal of Cancer.

[6]  M. Kallioinen,et al.  Prognostic value of MMP‐2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma , 1998, The Journal of pathology.

[7]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[8]  T. Turpeenniemi‐Hujanen,et al.  Modulation of Mr 72,000 and Mr 92,000 type‐IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma , 1994, International journal of cancer.

[9]  T. Turpeenniemi‐Hujanen,et al.  Matrix Metalloproteinase-2 (MMP-2) is Associated with the Risk for a Relapse in Postmenopausal Patients with Node-Positive Breast Carcinoma Treated with Antiestrogen Adjuvant Therapy , 2004, Breast Cancer Research and Treatment.

[10]  T. Yoshikawa,et al.  Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma , 2001, The British journal of surgery.

[11]  T. Yoshikawa,et al.  Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma , 2001, Cancer.

[12]  H. Kanayama,et al.  Prognostic values of matrix metalloproteinase‐2 and tissue inhibitor of metalloproteinase‐2 expression in bladder cancer , 1998 .

[13]  Bao Q. Pham,et al.  Curcuminoids Inhibit the Angiogenic Response Stimulated by Fibroblast Growth Factor-2, Including Expression of Matrix Metalloproteinase Gelatinase B* , 2000, The Journal of Biological Chemistry.

[14]  W. Linehan,et al.  Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. , 1997, Urology.

[15]  M. Dardenne.  Role of thymic peptides as transmitters between the neuroendocrine and immune systems. , 1999, Annals of medicine.

[16]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[17]  G. Fuller,et al.  Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo , 2004, Clinical and Experimental Metastasis.

[18]  J. Furuyama,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. , 1995, Journal of neurosurgery.

[19]  B. Davidson,et al.  Expression of Matrix Metalloproteinase-9 in Squamous Cell Carcinoma of the Uterine Cervix—Clinicopathologic Study Using Immunohistochemistry and mRNAin SituHybridization , 1999 .

[20]  U. Puistola,et al.  Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa gelatinase A (MMP-2). , 1997, Gynecologic oncology.

[21]  D. Fishman,et al.  Production of extracellular matrix‐degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells , 1997, Cancer.

[22]  H. Joensuu,et al.  Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer , 2005, Breast Cancer Research and Treatment.

[23]  L. Liotta,et al.  Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas , 2004, Clinical & Experimental Metastasis.

[24]  Y. Soini,et al.  Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation. , 2000, American journal of clinical pathology.

[25]  H. Nielsen,et al.  High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Nithya Ramnath,et al.  Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Zhang,et al.  Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. , 2003, World journal of gastroenterology.

[28]  T. Turpeenniemi‐Hujanen,et al.  Recombinant interferon alpha and gamma modulate the invasive potential of human melanoma in vitro , 1991, International journal of cancer.

[29]  L. Liotta,et al.  Elevated Levels of Mr 92,000 Type IV Collagenase in Human Brain Tumors , 1993 .

[30]  J. Foidart,et al.  Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. , 1998, British Journal of Cancer.

[31]  T. Turpeenniemi‐Hujanen,et al.  The Absence of Immunoreactivity for Tissue Inhibitor of Metalloproteinase-1 (TIMP-1), but Not for TIMP-2, Protein Is Associated with a Favorable Prognosis in Aggressive Breast Carcinoma , 2005, Oncology.

[32]  T. Turpeenniemi‐Hujanen,et al.  Expression of Matrix Metalloproteinase-9 in Head and Neck Squamous Cell Carcinoma , 2004, Clinical Cancer Research.

[33]  J. Mohler,et al.  In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer , 1997, Clinical & Experimental Metastasis.

[34]  I. Campbell,et al.  Distinct Expression Patterns and Levels of Enzymatic Activity of Matrix Metalloproteinases and Their Inhibitors in Primary Brain Tumors , 2001, Journal of neuropathology and experimental neurology.

[35]  T. Turpeenniemi‐Hujanen,et al.  High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma , 2004, Breast Cancer Research and Treatment.

[36]  W. Mutschler,et al.  Prognostic impact of matrix metalloproteinase‐9 in operable non‐small cell lung cancer , 2003, International journal of cancer.

[37]  S. Itohara,et al.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.

[38]  J. Carmichael,et al.  Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. , 1993, Journal of the National Cancer Institute.

[39]  H. Hoshiai,et al.  Immunohistochemical Studies on Matrix Metalloproteinase‐9 (MMP‐9) and Type‐IV Collagen in Endometrial Carcinoma , 1997, The journal of obstetrics and gynaecology research.

[40]  P. Pääkkö,et al.  Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker inbladder cancer , 2003 .

[41]  Selvaggi,et al.  Angiogenesis extent and expression of matrix metalloproteinase‐2 and ‐9 correlate with upgrading and myometrial invasion in endometrial carcinoma , 1999, European journal of clinical investigation.

[42]  F. Hamdy,et al.  Localization and quantification of mRNA for matrix metalloproteinase‐2 (MMP‐2) and tissue inhibitor of matrix metalloproteinase‐2 (TIMP‐2) in human benign and malignant prostatic tissue , 1997, The Prostate.

[43]  T. Kurizaki,et al.  Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. , 1998, Oncology reports.

[44]  S. Singletary,et al.  Prognostic Factors in Node-Negative Breast Cancer: A Review of Studies With Sample Size More Than 200 and Follow-Up More Than 5 Years , 2002, Annals of surgery.

[45]  J. Nesland,et al.  High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  M. Cilli,et al.  TIMP‐2 over‐expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis , 1998 .

[47]  Y. DeClerck,et al.  Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. , 1994, Cancer research.

[48]  T. Lah,et al.  Proteases in brain tumour progression , 2003, Acta Neurochirurgica.

[49]  C. Sheehan,et al.  Prognostic Significance of Matrix Metalloproteinase 2 and Tissue Inhibitor of Metalloproteinase 2 Expression in Prostate Cancer , 2003, Modern Pathology.

[50]  M. Nakajima,et al.  Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. , 1998, British Journal of Cancer.

[51]  L. Liotta,et al.  Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. , 1991, Cancer research.

[52]  A. Noël,et al.  High levels of TIMP‐2 correlate with adverse prognosis in breast cancer , 2000, International journal of cancer.

[53]  L. Liotta,et al.  Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo , 2004, Clinical & Experimental Metastasis.

[54]  B. C. Patterson,et al.  Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.

[55]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[56]  L. Hefler,et al.  Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer. , 1999, Anticancer research.

[57]  C. Sheehan,et al.  Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  E. D. Bal de Kier Joffé,et al.  Circulating 92‐kilodalton matrix metalloproteinase (MMP‐9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma , 2002, Cancer.

[59]  S. Itohara,et al.  In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. , 2002, Pharmacological research.

[60]  E. Masini,et al.  Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck , 2002, Cancer.

[61]  L. Liotta,et al.  Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. , 1990, Cancer research.

[62]  T. Yoshikawa,et al.  Tissue inhibitor of matrix metalloproteinase‐1 in the plasma of patients with gastric carcinoma , 1999, Cancer.

[63]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[64]  B. Davidson,et al.  MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. , 1999, Gynecologic oncology.

[65]  M. Kallioinen,et al.  MATRIX METALLOPROTEINASE‐2 (72 kD TYPE IV COLLAGENASE) EXPRESSION OCCURS IN THE EARLY STAGE OF HUMAN MELANOCYTIC TUMOUR PROGRESSION AND MAY HAVE PROGNOSTIC VALUE , 1996, The Journal of pathology.

[66]  D. Grignon,et al.  High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. , 1996, Cancer research.

[67]  M. Klempner,et al.  Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis , 1998, Cancer.

[68]  A. Stoppacciaro,et al.  Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor , 1994, International journal of cancer.

[69]  J. Folkman,et al.  Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance* , 1999, The Journal of Biological Chemistry.

[70]  C. Thorns,et al.  Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. , 2003, Anticancer research.

[71]  C. Bucana,et al.  Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  A. Scorilas,et al.  Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negativeatients , 2001, British Journal of Cancer.

[73]  K. Stefanaki,et al.  Enhanced mRNA expression of tissue inhibitor of metalloproteinase‐1 (TIMP‐1) in breast carcinomas is correlated with adverse prognosis , 2002, The Journal of pathology.

[74]  M. Polette,et al.  Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses , 1997, International Journal of Cancer.

[75]  T. Turpeenniemi‐Hujanen,et al.  Matrix Metalloproteinase-2 (MMP-2) in T1–2N0 breast carcinoma , 2004, Breast Cancer Research and Treatment.

[76]  C. Romanini,et al.  Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. , 1995, Anticancer research.

[77]  D. Grignon,et al.  Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  S. Kamidono,et al.  Elevation of serum levels of matrix metalloproteinase‐2 and ‐3 as new predictors of recurrence in patients with urothelial carcinoma , 1996, Cancer.

[79]  L. Liotta,et al.  Laminin receptors, collagenase IV and prognosis in node‐negative breast cancers , 1991, International journal of cancer.

[80]  T. Turpeenniemi‐Hujanen,et al.  Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. , 2005, Cancer letters.

[81]  Y. Okada,et al.  Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. , 1994, Journal of neurosurgery.

[82]  A. Reiner,et al.  Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. , 1998, Microvascular research.

[83]  M. Duffy,et al.  High levels of tissue inhibitor of metalloproteinase‐1 predict poor outcome in patients with breast cancer , 1999, International journal of cancer.

[84]  T. Turpeenniemi‐Hujanen,et al.  Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. , 2000, Anticancer research.

[85]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[86]  G. Amorino,et al.  Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. , 1998, The American journal of pathology.

[87]  C. Blomqvist,et al.  A High Serum Matrix Metalloproteinase-2 Level Is Associated with an Adverse Prognosis in Node-Positive Breast Carcinoma , 2004, Clinical Cancer Research.

[88]  S. Kitazawa,et al.  Serum matrix metalloproteinase‐2 and its density in men with prostate cancer as a new predictor of disease extension , 1998, International journal of cancer.

[89]  G. Stamp,et al.  Expression and activity of MMPS and their regulators in ovarian cancer , 1994, International journal of cancer.

[90]  M. Stack,et al.  A Plasma Membrane-associated Component of Ovarian Adenocarcinoma Cells Enhances the Catalytic Efficiency of Matrix Metalloproteinase-2 (*) , 1995, The Journal of Biological Chemistry.

[91]  D. Cheresh,et al.  Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.

[92]  T. Turpeenniemi‐Hujanen,et al.  Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma , 2003, British Journal of Cancer.

[93]  T. Turpeenniemi‐Hujanen,et al.  Matrix metalloproteinase‐2 immunoreactive protein , 1998, Cancer.

[94]  T. Turpeenniemi‐Hujanen,et al.  Matrix Metalloproteinase 2 (MMP-2) Immunoreactive Protein is Associated with Poor Grade and Survival in Brain Neoplasms , 2004, Journal of Neuro-Oncology.

[95]  P. Black,et al.  Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. , 2001, Cancer research.

[96]  M. Stearns,et al.  Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer. , 1996, Oncology research.

[97]  K. O'Byrne,et al.  Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[98]  A. Paradiso,et al.  Gelatinase levels in male and female breast cancer. , 2002, Biochemical and biophysical research communications.

[99]  J. Risteli,et al.  Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. , 1999, Anticancer research.

[100]  T. Hurskainen,et al.  Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[101]  C. Azuma,et al.  Type‐IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues , 1994, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[102]  G I Murray,et al.  Matrix metalloproteinases in tumour invasion and metastasis , 1999, The Journal of pathology.

[103]  M. Kallioinen,et al.  Matrix metalloproteinase‐2 (MMP‐2) immunoreactive protein—a new prognostic marker in uveal melanoma? , 1999, The Journal of pathology.

[104]  L. Parvinen,et al.  Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma. , 2000, Acta oncologica.

[105]  R. Béliveau,et al.  Expression of matrix metalloproteinases and their inhibitors in human brain tumors , 2004, Clinical & Experimental Metastasis.

[106]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[107]  G. Stamp,et al.  Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma , 1997, The Journal of pathology.

[108]  K. Iwata,et al.  Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analyses. , 1996, The Biochemical journal.

[109]  U. Puistola,et al.  Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. , 1999, Gynecologic oncology.

[110]  T. Turpeenniemi‐Hujanen,et al.  MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma , 1999, Breast Cancer Research and Treatment.

[111]  L. Liotta,et al.  Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[112]  E. Armanasco,et al.  Plasma MMP‐9 (92 kDa‐MMP) activity is useful in the follow‐up and in the assessment of prognosis in breast cancer patients , 2003, International journal of cancer.

[113]  F. Sarkar,et al.  Enhanced expression of tissue inhibitor of metalloproteinase‐2 (TIMP‐2) in the stroma of breast carcinomas correlates with tumor recurrence , 1994, International journal of cancer.

[114]  M. Stearns,et al.  IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. , 1997, Invasion & metastasis.

[115]  J. Nesland,et al.  High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma , 2004, Clinical & Experimental Metastasis.

[116]  K. Rubin,et al.  Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage. , 1997, British Journal of Cancer.

[117]  J. Rhim,et al.  Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[118]  U. Puistola,et al.  Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer. , 1999, Gynecologic oncology.

[119]  E. Miyagi,et al.  Marked induction of gelatinases, especially type B, in host fibroblasts by human ovarian cancer cells in athymic mice , 1995, Clinical & Experimental Metastasis.

[120]  P. Libby,et al.  T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. , 1999, The American journal of pathology.

[121]  Y. Soini,et al.  Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. , 2005, Anticancer research.

[122]  G. Gasparini,et al.  Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. , 2001, Critical reviews in oncology/hematology.

[123]  S. Loening,et al.  Plasma concentrations of metalloproteinases (MMP-1, MMP-3) and their inhibitors in patients with prostate cancer , 1998, Der Urologe A.

[124]  K. Yasumoto,et al.  Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung , 1997, Pathology international.